Research
Methylcobalamin
49 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Maternal supplementation of vitamin Bin predominantly vegetarian pregnant women improves their vitamin Bstatus and the neurodevelopment of their infants: the MATCOBIND multicentric double-blind randomised control trial.
This double-blind, randomised controlled trial studied the effects of daily supplementation with 250 µg vs 50 µg of methyl-cobalamin in predominantly vegetarian pregnant women. The higher dose significantly improved infant mental developmental quotients and maternal vitamin B12 status compared to the lower dose.
Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined with Dapagliflozin as Type 2 Diabetes Mellitus Routine Treatment: A Controlled Randomized, Double-blind Trial.
Controlled randomized, double-blind trial evaluating the effects of methylcobalamin (vitamin B12) supplementation on BMI and HbA1c levels in type 2 diabetic patients treated with dapagliflozin. The co-administration of vitamin B12 significantly decreased HbA1c levels and improved BMI compared to dapagliflozin alone.
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
Multicentre, double blind, randomised, placebo controlled, phase 3 trial evaluating methylcobalamin for preventing hand-foot syndrome in patients with HER2 negative early breast cancer receiving capecitabine. Methylcobalamin significantly reduced the incidence of grade ≥2 hand-foot syndrome without unexpected safety concerns.
Dapagliflozin combined with methylcobalamin in the treatment of type 2 diabetes mellitus with peripheral neuropathy: a systematic review and meta-analysis.
This systematic review and meta-analysis assessed the efficacy and safety of dapagliflozin combined with methylcobalamin in treating diabetic peripheral neuropathy in type 2 diabetes mellitus patients. The combination therapy significantly improved nerve conduction velocities and glycemic control without a significant increase in adverse events.
The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis collates studies using cobalamin (B12) as a treatment for autism spectrum disorder (ASD). It includes 17 studies, with improvements observed in metabolic abnormalities and clinical symptoms such as communication, daily living skills, and social skills. Adverse events were generally mild and not significantly different from placebo. B12, particularly subcutaneously injected methylcobalamin, shows promise as a treatment for ASD.
Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis.
Meta-analysis of 13 RCTs with 1148 participants evaluating fasudil combined with methylcobalamin or lipoic acid for diabetic peripheral neuropathy. Combination therapy was superior to monotherapy in improving nerve conduction velocities and neuropathic symptoms, with no serious adverse events reported.
Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials.
Meta-analysis of 16 RCTs with 1136 participants comparing methylcobalamin plus prostaglandin E1 combination therapy to prostaglandin E1 monotherapy for diabetic peripheral neuropathy. The combination therapy showed superior clinical efficacy and improved nerve conduction velocities without serious adverse events.
Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy.
Meta-analysis comparing the efficacy and safety of prostaglandin E1 plus methylcobalamin (PGE1-MC) versus methylcobalamin alone (MC) for diabetic peripheral neuropathy. Analysis of 26 RCTs with 2,107 individuals showed PGE1-MC combination therapy was significantly better than MC monotherapy in improving nerve conduction velocities. No serious adverse events were reported, but the conclusion is limited by poor methodological quality of included studies.
What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.
Systematic review of interventions to improve walking ability in neurogenic claudication with lumbar spinal stenosis. Low quality evidence suggests prostaglandins and very low quality evidence suggests gabapentin or methylcobalamin may improve walking distance. Overall, evidence quality is low to very low, limiting clinical recommendations.
Efficacy of L-methylfolate and methylcobalamin in treating resistant hypertension associated with elevated serum homocysteine in hemodialysis patients.
RCT of 51 ESRD patients with resistant hypertension on hemodialysis, comparing daily supplementation of L-methylfolate and methylcobalamin to no medication. The intervention group showed significant reductions in serum homocysteine levels and blood pressure after three months.
Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study.
Open-label extension of a phase 2/3 RCT investigating the long-term safety of ultra-high-dose methylcobalamin in 144 patients with advanced ALS. The study found a high incidence of adverse events, but only 3.5% were adverse drug reactions, none leading to discontinuation or death. The survival rate at 52 weeks was 85.7%, with no clear deterioration in survival rate or physical function.
Prognostic Impact of Serum Homocysteine-Lowering Therapy on Patients with Hemorrhagic Stroke and Its Influence on National Institutes of Health Stroke Scale and China Stroke Scale Scores.
Double-blind RCT of 120 patients with hemorrhagic stroke and hyperhomocysteinemia comparing high-dose vs low-dose folic acid, methylcobalamin, and vitamin B6. The high-dose group showed improved oxidative stress, vascular endothelial function, and lower NIHSS and CSS scores, indicating enhanced prognosis and neurological function.
Pain Fluctuations of Women with Subacute Herpetic Neuralgia During Local Methylcobalamin in Combination with Lidocaine Treatment: A Single-Blinded Randomized Controlled Trial.
RCT evaluating the efficacy of methylcobalamin combined with lidocaine for subacute herpetic neuralgia in 79 women. The combination treatment significantly reduced pain scores compared to the control group, with a notable circadian rhythm in pain levels.
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
This randomized clinical trial evaluated the efficacy and safety of ultrahigh-dose methylcobalamin in patients with early-stage amyotrophic lateral sclerosis (ALS). The study found that methylcobalamin slowed functional decline compared to placebo, with a 1.97-point greater improvement in ALSFRS-R total score over 16 weeks. The incidence of adverse events was similar between the groups.
A randomized comparative study of methylcobalamin, methylcobalamin plus pregabalin and methylcobalamin plus duloxetine in patients of painful diabetic neuropathy.
A randomized comparative study of methylcobalamin, methylcobalamin plus pregabalin, and methylcobalamin plus duloxetine in 100 patients with painful diabetic neuropathy. Group C (methylcobalamin plus duloxetine) showed the highest efficacy in improving vibration perception, pressure sensation, and thermal sensitivity, and reducing pain scores, while Group B (methylcobalamin plus pregabalin) was safer.
Local Administration of Methylcobalamin for Subacute Ophthalmic Herpetic Neuralgia: A Randomized, Phase III Clinical Trial.
A randomized controlled trial evaluated the efficacy of local methylcobalamin injection for subacute ophthalmic herpetic neuralgia. Pain scores were significantly reduced in the local injection group compared to systemic administration, with a greater proportion of patients experiencing clinically relevant pain reduction and reduced analgesic use.
Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study.
RCT evaluating the efficacy and safety of intramuscular ultra-high-dose methylcobalamin in 373 ALS patients. No significant differences were found in primary endpoints for the whole cohort, but early-treated patients showed longer time intervals to primary events and less decrease in ALSFRS-R score.
A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients.
RCT of 279 older MCI patients with elevated serum homocysteine, testing B vitamins (methylcobalamin and folic acid) supplementation for 24 months. The supplement lowered serum homocysteine but did not reduce cognitive decline. It improved executive function and reduced depressive symptoms at month 12, though effects were not sustained at month 24. Aspirin use negatively interacted with B supplements on cognitive functioning.
A randomized placebo controlled trial of vitamin Bsupplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B.
RCT of 271 older diabetic outpatients with borderline low vitamin B12 levels, testing methylcobalamin 1000 μg daily versus placebo for 27 months. Vitamin B12 supplementation reduced serum MMA and homocysteine but did not prevent cognitive decline.
Local Injection of Methylcobalamin Combined with Lidocaine for Acute Herpetic Neuralgia.
RCT of 204 patients with acute herpetic neuralgia comparing local injection of methylcobalamin combined with lidocaine to intramuscular methylcobalamin with local lidocaine. The treatment group showed significant reductions in pain scores and improved quality of life compared to controls, with optimal results when administered within 4-7 days of onset.
Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy.
Meta-analysis comparing the efficacy and safety of lipoic acid plus methylcobalamin combination therapy versus methylcobalamin alone in diabetic peripheral neuropathy. The combination therapy was significantly superior in improving nerve conduction velocity and neuropathic symptoms, with no serious adverse events reported.
Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial.
This multicenter, randomized, double-blind, placebo-controlled trial involved 214 patients with type 2 diabetes and neuropathy. The study tested the effects of Metanx (L-methylfolate, methylcobalamin, and pyridoxal-5'-phosphate) on sensory neuropathy. While there was no significant effect on vibration perception threshold, patients reported symptomatic relief and improved Neuropathy Total Symptom Scores. Quality-of-life measures also improved, and homocysteine levels decreased significantly.
The Efficacy of Ultrasound-Guided Thoracic Paravertebral Blocks Using a Novel Analgesic Regimen for Thoracic Herpes Zoster-Associated Pain: A Randomized Controlled Trial.
RCT evaluating the efficacy of a novel analgesic mixture containing parecoxib and methylcobalamin for thoracic herpes zoster neuralgia. The novel mixture showed superior pain relief and sleep quality improvement compared to the control, with no additional safety concerns.
Efficacy of Oral Vitamin B-12 at 1000 μg Compared with 2000 μg on Neuropathic Outcomes in Patients with Diabetic Peripheral Neuropathy and Low Serum Vitamin B-12: a Randomized Clinical Trial.
This randomized controlled trial compared the effects of 1000 μg and 2000 μg daily doses of oral vitamin B-12 on neuropathic outcomes in patients with diabetic peripheral neuropathy and low serum vitamin B-12. Both doses significantly improved neuropathy symptoms, with no significant difference between the groups. The 2000 μg dose resulted in higher serum B-12 levels but did not provide additional neuropathic or metabolic benefits.
Efficacy of oral compared with intramuscular vitamin B-12 supplementation after Roux-en-Y gastric bypass: a randomized controlled trial.
RCT comparing oral methylcobalamin supplementation to intramuscular hydroxocobalamin injections in 50 RYGB patients with low serum B-12. Both methods normalized vitamin B-12 levels, with no significant difference in efficacy. MMA and Hcy concentrations decreased significantly in both groups.
Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
RCT of 104 multiple myeloma patients with chemotherapy-induced peripheral neuropathy comparing methylcobalamin alone to methylcobalamin combined with acupuncture. The combination group showed significantly greater improvements in pain, daily activity, and nerve conduction velocity.
Local Administration of Methylcobalamin and Lidocaine for Acute Ophthalmic Herpetic Neuralgia: A Single-Center Randomized Controlled Trial.
RCT evaluating the efficacy of combined methylcobalamin and lidocaine for acute ophthalmic herpetic neuralgia (AOHN) in 98 patients. The treatment significantly reduced rash healing time, pain intensity, and improved quality of life compared to controls. Methylcobalamin intervention within 4 to 7 days of onset showed significant therapeutic benefits.
A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia.
A single-center randomized controlled trial evaluated the efficacy of local methylcobalamin injection in 98 subjects with subacute herpetic neuralgia. The injected methylcobalamin group showed significant pain reduction and improved quality of life compared to oral methylcobalamin and lidocaine groups.
A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people.
RCT of 140 subjects with Alzheimer disease or vascular dementia testing methylcobalamin and folic acid supplementation for 24 months. The supplement group showed reduced plasma homocysteine levels, but no significant difference in global cognitive decline. However, among those with elevated homocysteine, the supplement group had a smaller decline in MDRS construction domain.
[Clinical observation on diabetic peripheral neuropathy treated with electroacupuncture and acupoint injection].
RCT comparing electroacupuncture plus acupoint injection with methylcobalamin to acupoint injection alone in 60 patients with diabetic peripheral neuropathy. The combined therapy showed higher effective rates and improved nerve conduction velocity compared to acupoint injection alone.
The efficacy and safety of intramuscular injections of methylcobalamin in patients with chronic nonspecific low back pain: a randomised controlled trial.
RCT of 60 patients with chronic nonspecific low back pain comparing intramuscular methylcobalamin injections to placebo. The methylcobalamin group showed significant improvement in Oswestry Disability Index and Visual Analogue Scale pain scores compared to placebo, with only minor adverse reactions reported.
Effects of plasma homocysteine levels on serum HTase/PON activity in patients with type 2 diabetes.
RCT with 90 type 2 diabetes patients divided into three groups: no supplementation, folic acid, and folic acid with methylcobalamin. Folic acid, with or without methylcobalamin, significantly reduced plasma homocysteine levels and increased HTase/PON activity, suggesting a protective mechanism against vascular diabetic complications.
[Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus].
RCT studying the effects of methylcobalamin and folic acid on plasma homocysteine levels and HTase/PON activity in 120 patients with type 2 diabetes mellitus. Methylcobalamin and folic acid treatment decreased homocysteine levels and increased HTase/PON activity, with combination therapy being more effective.
Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients.
Randomized trial in 62 chronic hemodialysis patients assessing the effects of intravenous methylcobalamin and oral folic acid on fasting homocysteine levels. Folic acid alone effectively normalized homocysteine levels, while the addition of methylcobalamin showed no additional benefit.
Methylcobalamin as an adjuvant medication in conservative treatment of lumbar spinal stenosis.
Single blind control trial with 152 patients to assess the effects of methylcobalamin on lumbar spinal stenosis treatment. Patients received conventional management with or without methylcobalamin for 6 months. No significant difference in pain improvement and neurological signs between groups, except better neurogenic claudication distance in the methylcobalamin group.
Sublingual vitamin B12 compared to intramuscular injection in patients with type 2 diabetes treated with metformin: a randomised trial.
RCT comparing a single 1mg intramuscular hydroxocobalamin injection with a 3-month course of 1mg/day sublingual methylcobalamin supplements on serum vitamin B12 concentrations in type 2 diabetes patients treated with metformin. After 3 months, the sublingual group had higher serum B12 levels than the injection group. Both methods corrected decreased serum vitamin B12 levels.
Randomized double blinded placebo controlled trial comparing diclofenac and piroxicam in management of acute renal colic and its clinical implications.
RCT comparing sublingual piroxicam 40 mg with intramuscular diclofenac 75 mg in 100 patients with acute renal colic. Group A received diclofenac and methylcobalamin, while Group B received piroxicam. Both groups showed significant pain relief, with no significant difference between them. The study also analyzed factors affecting pain severity and relief.
Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study
Open label, randomized controlled pilot study comparing pregabalin monotherapy to a combination of pregabalin, methylcobalamin, and alpha lipoic acid in 30 patients with type 2 diabetes-associated peripheral neuropathy. The combination group showed significant improvement in pain relief, sleep interference, and nerve conduction velocity, though small sample size limits the significance of differences between groups.
Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study
Open label, randomized controlled pilot study comparing pregabalin with a combination of pregabalin, methylcobalamin, and alpha lipoic acid in 30 patients with type 2 diabetes-associated peripheral neuropathy. The combination group showed significant improvement in pain, sleep interference, and nerve conduction velocity, though small sample size limits the significance of differences between groups.
Safety and efficacy of intravenous ultra-high dose methylcobalamin treatment for peripheral neuropathy: a phase I/II open label clinical trial.
Phase I/II open label clinical trial assessing the safety and efficacy of intravenous ultra-high dose methylcobalamin (MeCbl) for peripheral neuropathy. Fourteen patients were treated, with seven showing improvement in the MRC sum score and five showing no change or worsening. Two patients discontinued due to adverse effects.
Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study.
A 24-week, double-blind, randomized placebo-controlled study evaluated the efficacy and tolerability of an AGEs inhibitor (benfotiamine, pyridoxamine, methylcobalamin) in 30 OA patients. The study found significant improvements in pain, inflammation, and mobility scores in the treatment group compared to placebo.
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
RCT of 40 hemodialysis patients comparing coadministration of intravenous methylcobalamin and oral folate to oral folate alone. The methylcobalamin group showed greater normalization of plasma homocysteine levels, a larger decrease in serum ADMA levels, and reduced arterial stiffness, suggesting potential cardiovascular benefits.
Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation.
RCT investigating the effect of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Methylcobalamin significantly reduced fasting tHcy levels, suggesting its benefit in improving heart health in patients with chronic renal failure.
Double-blind test on the efficacy of methylcobalamin on sleep-wake rhythm disorders.
Double-blind test examining the therapeutic effect of methylcobalamin (Met-12) on sleep-wake rhythm disorders. The test group showed a higher percentage of improvement compared to the control group, but the difference was not significant. Results suggested a beneficial effect, though improvement was inconsistent.
Methylcobalamin treatment of Bell's palsy.
Open randomized trial of 60 patients with Bell's palsy comparing steroid, methylcobalamin, and methylcobalamin + steroid treatments. Methylcobalamin groups showed significantly faster recovery of facial nerve function and better improvement of concomitant symptoms compared to the steroid group.
Effect of methylcobalamin in accommodative dysfunction of eye by visual load.
The study investigated the effect of methylcobalamin on accommodative function in subjects with deteriorated accommodation due to visual work. Methylcobalamin reduced small fluctuations of accommodation compared to non-administered and placebo groups, indicating a positive effect on accommodation.
Measuring vitamin B-12 bioavailability with [13C]-cyanocobalamin in humans.
The study measured the bioavailability of [13C]-cyanocobalamin in humans, assessing the effect of parenteral replenishment of vitamin B-12 on bioavailability. Results showed dose-dependent bioavailability, with a 1.9-fold increase after parenteral replenishment in deficient individuals.
Analgesic efficacy and safety of medical therapy alone vs combined medical therapy and extraoral glossopharyngeal nerve block in glossopharyngeal neuralgia.
This randomized, prospective, active-controlled study compared the analgesic efficacy and safety of medical therapy alone versus combined medical therapy and extraoral glossopharyngeal nerve block in patients with glossopharyngeal neuralgia. Both groups showed significant pain reduction and improved quality of life, with no significant hemodynamic adverse outcomes. The study supports a polypharmacy approach for difficult-to-treat pain conditions.
Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study.
Double-blind controlled study comparing ultrahigh-dose and low-dose methylcobalamin on compound muscle action potentials in 24 patients with amyotrophic lateral sclerosis. The ultrahigh-dose group showed a significant increase in CMAP amplitude at 4 weeks, suggesting potential benefits for muscle function.